Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Brain Neoplasms × Eflornithine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroblastoma 8 Precancerous Conditions 3 Adenomatous Polyposis Coli 3 Prostatic Neoplasms 2 Medulloblastoma 2 Glioma 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Urinary Bladder Neoplasms 1 Typical Teratoid Rhabdoid Tumor 1 Skin Neoplasms 1 Sarcoma, Ewing 1 Osteosarcoma Recurrent 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Melanoma 1 Lung Neoplasms 1 Keratosis, Actinic 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Colonic Polyps 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Basal Cell 1 Breast Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Adenomatous Polyps 1

Interventions

Temozolomide 134 Radiosurgery 113 Radiotherapy 89 Bevacizumab 85 Magnetic Resonance Spectroscopy 66 Carboplatin 44 pembrolizumab 31 Etoposide 31 Surgical Procedures, Operative 29 Radiation 28 Nivolumab 28 Irinotecan 28 Cyclophosphamide 28 Erlotinib Hydrochloride 26 Carmustine 24 Lomustine 22 Filgrastim 21 Trastuzumab 20 Ipilimumab 20 Cisplatin 20 Aminolevulinic Acid 20 Magnetic Resonance Imaging 19 Surveys and Questionnaires 18 Vincristine 17 Specimen Handling 17 Mental Status and Dementia Tests 17 Capecitabine 17 Pemetrexed 16 Topotecan 15 Lapatinib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02796261 2022-01-21

STELLAR

Orbus Therapeutics, Inc.

Phase 3 Unknown

Astrocytoma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡